NVIDIA's BioNeMo platform has signed co-innovation partnerships with Eli Lilly and Thermo Fisher, embedding AI foundation models directly into enterprise drug discovery pipelines. The deals are not pilots — they are production infrastructure generating vendor lock-in at scale.
Novo Nordisk accelerated the same pattern by licensing its cell therapy program to Cellular Intelligence, an AI-native spinout, while shutting its internal cell therapy unit.1 The Danish pharma giant returns its focus to GLP-1, its dominant commercial franchise. Cellular Intelligence will advance a Parkinson's disease program using AI-driven development methods.1
The commercial logic is straightforward. Major pharma companies — from Indianapolis to Copenhagen — are offloading high-risk, capital-intensive programs to AI-native partners that absorb early-stage uncertainty faster and cheaper than internal units can.
BioNeMo supplies foundation models for protein structure prediction, molecular docking, and generative chemistry. Once embedded in Lilly's or Thermo Fisher's pipelines, switching costs rise sharply. Infrastructure commitment follows adoption.
A wave of commercial foundation model platform launches in 2025 and 2026 has turned AI adoption into a baseline requirement worldwide. Drug discovery programs without production AI pipelines are falling behind those that have them — in the US, Europe, and Asia alike.
For biotech startups globally, enterprise-grade AI infrastructure is becoming accessible through partnership arrangements, lowering barriers to capabilities once available only to top-tier labs. The tradeoff is vendor concentration: dependence on NVIDIA's stack ties discovery capacity to a single provider.
Novo Nordisk's decision signals that even top-tier international pharma has concluded internal AI-native units aren't cost-effective when external partners move faster.1 The model — spin out, license, partner — is spreading from North America to European and Asian R&D hubs.
Fourteen backing claims tracked across this signal cluster confirm the trend is broad and cross-border, not isolated. Companies that locked in early are setting the terms for how drug discovery operates at scale.
